Cardiovascular effects of relaxin: from basic science to clinical therapy

Xiao-Jun Du, Ross A D Bathgate, Chrishan S Samuel, Anthony M Dart, Roger James Summers

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Although substantial advances have been achieved in recent decades in the clinical management of heart diseases, new therapies that provide better or additional efficacy with minimal adverse effects are urgently required. Evidence that has accumulated since the 1990s indicates that the peptide hormone relaxin has multiple beneficial actions in the cardiovascular system under pathological conditions and, therefore, holds promise as a novel therapeutic intervention. Clinical trials for heart failure therapy using relaxin revealed several beneficial actions. Here we review findings from mechanistic and applied research in this field, comment on the outcomes of recent phase I/II clinical trails on patients with heart failure, and highlight settings of cardiovascular diseases where relaxin might be effective.
Original languageEnglish
Pages (from-to)48 - 58
Number of pages11
JournalNature Reviews Cardiology
Volume7
Issue number1
DOIs
Publication statusPublished - 2010

Cite this

Du, Xiao-Jun ; Bathgate, Ross A D ; Samuel, Chrishan S ; Dart, Anthony M ; Summers, Roger James. / Cardiovascular effects of relaxin: from basic science to clinical therapy. In: Nature Reviews Cardiology. 2010 ; Vol. 7, No. 1. pp. 48 - 58.
@article{044ffd3cc79e4e6f9de0ef1d2b1d0954,
title = "Cardiovascular effects of relaxin: from basic science to clinical therapy",
abstract = "Although substantial advances have been achieved in recent decades in the clinical management of heart diseases, new therapies that provide better or additional efficacy with minimal adverse effects are urgently required. Evidence that has accumulated since the 1990s indicates that the peptide hormone relaxin has multiple beneficial actions in the cardiovascular system under pathological conditions and, therefore, holds promise as a novel therapeutic intervention. Clinical trials for heart failure therapy using relaxin revealed several beneficial actions. Here we review findings from mechanistic and applied research in this field, comment on the outcomes of recent phase I/II clinical trails on patients with heart failure, and highlight settings of cardiovascular diseases where relaxin might be effective.",
author = "Xiao-Jun Du and Bathgate, {Ross A D} and Samuel, {Chrishan S} and Dart, {Anthony M} and Summers, {Roger James}",
year = "2010",
doi = "10.1038/nrcardio.2009.198",
language = "English",
volume = "7",
pages = "48 -- 58",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "1",

}

Cardiovascular effects of relaxin: from basic science to clinical therapy. / Du, Xiao-Jun; Bathgate, Ross A D; Samuel, Chrishan S; Dart, Anthony M; Summers, Roger James.

In: Nature Reviews Cardiology, Vol. 7, No. 1, 2010, p. 48 - 58.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cardiovascular effects of relaxin: from basic science to clinical therapy

AU - Du, Xiao-Jun

AU - Bathgate, Ross A D

AU - Samuel, Chrishan S

AU - Dart, Anthony M

AU - Summers, Roger James

PY - 2010

Y1 - 2010

N2 - Although substantial advances have been achieved in recent decades in the clinical management of heart diseases, new therapies that provide better or additional efficacy with minimal adverse effects are urgently required. Evidence that has accumulated since the 1990s indicates that the peptide hormone relaxin has multiple beneficial actions in the cardiovascular system under pathological conditions and, therefore, holds promise as a novel therapeutic intervention. Clinical trials for heart failure therapy using relaxin revealed several beneficial actions. Here we review findings from mechanistic and applied research in this field, comment on the outcomes of recent phase I/II clinical trails on patients with heart failure, and highlight settings of cardiovascular diseases where relaxin might be effective.

AB - Although substantial advances have been achieved in recent decades in the clinical management of heart diseases, new therapies that provide better or additional efficacy with minimal adverse effects are urgently required. Evidence that has accumulated since the 1990s indicates that the peptide hormone relaxin has multiple beneficial actions in the cardiovascular system under pathological conditions and, therefore, holds promise as a novel therapeutic intervention. Clinical trials for heart failure therapy using relaxin revealed several beneficial actions. Here we review findings from mechanistic and applied research in this field, comment on the outcomes of recent phase I/II clinical trails on patients with heart failure, and highlight settings of cardiovascular diseases where relaxin might be effective.

UR - http://www.nature.com/nrcardio/journal/v7/n1/pdf/nrcardio.2009.198.pdf

U2 - 10.1038/nrcardio.2009.198

DO - 10.1038/nrcardio.2009.198

M3 - Article

VL - 7

SP - 48

EP - 58

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - 1

ER -